Table 2:
Clinicopathologic Characteristics of Patients with Pancreatic Ductal Adenocarcinoma With and Without Cancerization.
| COD Present (N=89) |
COD absent (N=85) |
All (N=174) |
P-value | |
|---|---|---|---|---|
| Tumor size and location | ||||
| Size (median [range]) (mm)* | 30 [0–75] | 25 [0–78] | 27 [0–78] | 0.287 |
| Head | 65 (73%) | 70 (82%) | 135 (78%) | 0.151 |
| Body or tail | 24 (27%) | 15 (18%) | 39 (22%) | |
| pT classification (AJCC 8th) | ||||
| pT0 | 0 (1%) | 1 (1%) | 1 (1%) | 0.345 |
| pTis | 1 (1%) | 0 (0%) | 1 (1%) | |
| pT1 | 25 (28%) | 31 (36%) | 56 (32%) | |
| pT2 | 51 (57%) | 42 (49%) | 93 (53%) | |
| pT3 | 12 (13%) | 10 (12%) | 22 (13%) | |
| pT4 | 0 (0%) | 1 (1%) | 1 (1%) | |
| pN classification (AJCC 8th) | ||||
| pN0 | 32 (36%) | 33 (39%) | 65 (37%) | 0.341 |
| pN1 | 32 (36%) | 36 (42%) | 68 (39%) | |
| pN2 | 25 (28%) | 16 (19%) | 41 (24%) | |
| pM classification (AJCC 8th) | ||||
| pM0 | 88 (99%) | 84 (99%) | 172 (99%) | 1.00 |
| pM1 | 1 (1%) | 1 (1%) | 2 (1%) | |
| pStage (AJCC 8th)** | ||||
| pStage 0 | 1 (1%) | 0 (0%) | 1 (1%) | 0.532 |
| pStage I | 30 (34%) | 29 (34%) | 59 (34%) | |
| pStage II | 32 (36%) | 37 (44%) | 69 (40%) | |
| pStage III | 25 (28%) | 17 (20%) | 42 (24%) | |
| pStage IV | 1 (1%) | 1 (1%) | 2 (1%) | |
| Lymphovascular invasion | ||||
| Present | 49 (55%) | 30 (35%) | 79 (45%) | 0.0100 |
| Absent | 40 (45%) | 55 (65%) | 95 (55%) | |
| Perineural invasion | ||||
| Present | 73 (82%) | 65 (76%) | 138 (79%) | 0.455 |
| Absent | 16 (18%) | 20 (24%) | 36 (21%) | |
| Final pancreatic margin | ||||
| Positive | 15 (17%) | 5 (6%) | 20 (11%) | 0.0313 |
| Negative | 74 (83%) | 80 (94%) | 154 (89%) | |
| Neoadjuvant therapy | ||||
| NAC | 27 (30%) | 25 (29%) | 52 (30%) | 0.99 |
| NAC+RT | 23 (26%) | 22 (26%) | 45 (26%) | |
| No treatment | 39 (44%) | 38 (45%) | 77 (45%) | |
*
Tumor size of invasive component
**
One pT0 case in NAC group was excluded according to the AJCC staging system.